Towards Healthcare

NEWS & INSIGHTS

Stay ahead of the curve with in-depth coverage of the latest breakthroughs, emerging trends, strategic developments, and transformative innovations shaping the future of healthcare, science, technology, and global business.

Kardium Secures $250 Million to Launch Innovative Globe System for Atrial Fibrillation Treatment
Date 03 July 2025

Kardium Secures $250 Million to Launch Innovative Globe System for Atrial Fibrillation Treatment

Which Company is Investing in Improving a Specific Treatment? Kardium Inc., a founder of the ‘Globe® Pulsed field system’, which is an innovative treatment for atrial fibrillation (...

Gilead's New HIV Drug 'Yeztugo' Shakes Up Market as GSK Prepares to Compete
Date 03 July 2025

Gilead's New HIV Drug 'Yeztugo' Shakes Up Market as GSK Prepares to Compete

Gilead's Chances Peak Until GSK’s Response to the Competition Announcement Gilead’s new PreP drug, ‘Yeztugo’, is said to be reaching sales of $4.5 billion, if GSK doesn&rsq...

BioVersys and Shionogi Partner to Develop New Antibiotics for Drug-Resistant Infections
Date 03 July 2025

BioVersys and Shionogi Partner to Develop New Antibiotics for Drug-Resistant Infections

BioVersys and Shionogi Joined Forces to Accelerate Research and Development Announcement BioVersys AG, a biopharmaceutical company known for its excellent research and development of antibacterial...

Rinri Gets UK Approval to Begin Clinical Trial for Groundbreaking Hearing Loss Therapy
Date 02 July 2025

Rinri Gets UK Approval to Begin Clinical Trial for Groundbreaking Hearing Loss Therapy

Rinri’s Clinical Trial Application, a First Approval of the Month Image Credits: Hearing Health & Technology Matters Announcement Rinri Therapeutics, a global company aiming to bring a ...

Crinetics to Present Latest Data on PALSONIFYâ„¢ and Atumelnant at ENDO 2025
Date 02 July 2025

Crinetics to Present Latest Data on PALSONIFYâ„¢ and Atumelnant at ENDO 2025

Another Innovation to be Launched at ENDO 2025 Image Credits: The Manila Times Announcement Crinetics Pharmaceuticals, Inc. is ready to showcase eight abstracts from its clinical development prog...

PHCbi to Distribute MaxCyte ExPERT Cell Engineering Platform in Japan
Date 02 July 2025

PHCbi to Distribute MaxCyte ExPERT Cell Engineering Platform in Japan

MaxCyte ExPERT Platform in Japan Image Credits: Galveston Country Daily News Announcement The PHC corporation, a biomedical division subsidiary of PHC Holdings Corporation, has entered an agreeme...

Summit Therapeutics and Revolution Medicines Partner to Develop Cancer Therapies
Date 02 July 2025

Summit Therapeutics and Revolution Medicines Partner to Develop Cancer Therapies

A Clinical Collaboration to Fuel the Healthcare Market Image Credits: Seeking Alpha Announcement Summit Therapeutics Inc., a biopharmaceutical oncology company, and Revolution Medicines Inc., a l...

HUTCHMED Gets China Approval for Lung Cancer Drug Combo with AstraZeneca
Date 01 July 2025

HUTCHMED Gets China Approval for Lung Cancer Drug Combo with AstraZeneca

HUTCHMED Received Approval from China Image Credits: Sharecast Announcement HUTCHMED (China) Limited has received approval from the China National Medical Products Administration (NMPA) for its n...

Riliprubart Gets Orphan Drug Status in Japan for CIDP Treatment
Date 01 July 2025

Riliprubart Gets Orphan Drug Status in Japan for CIDP Treatment

Riliprubart Received Orphan Drug Designation in Japan Image Credits: Western Slope Now Announcement The Japanese Ministry of Health, Labour and Welfare appointed riliprubart as an orphan drug des...

ESTEVE Acquires Global Rights to Caprelsa® from Sanofi to Treat Rare Thyroid Cancer
Date 01 July 2025

ESTEVE Acquires Global Rights to Caprelsa® from Sanofi to Treat Rare Thyroid Cancer

ESTEVE’s Agreement with Sanofi Image Credits: AInvest Announcement ESTEVE signed an agreement with Sanofi, a French multinational pharmaceutical and health-care company, to acquire Caprelsa...

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.